Investigating and modeling the differential DNA methylation for early lung adenocarcinoma diagnosis

Biomark Med. 2022 Sep;16(13):947-958. doi: 10.2217/bmm-2022-0240. Epub 2022 Aug 11.

Abstract

Background: Aberrant DNA methylations serve as rich sources of diagnostic biomarkers, but a further improvement in their accuracy and clinical utility is warranted. Methods: Large panel bisulfite sequencing was performed on paired normal and stage I/IV tumors from 226 lung adenocarcinoma cancer patients to characterize the differentially methylated regions (DMRs). Results: Random forest model achieved high prediction accuracy (sensitivity 96% and specificity 97.56%) to separate normal controls from both early and advanced cancer samples, which is superior to most previous prediction models tested in lung adenocarcinoma. Conclusion: Our results suggest that combining the random forest model with targeted bisulfite sequencing have great clinical potential to accurately predict and diagnose lung adenocarcinoma early during cancer screening.

Keywords: DNA methylation; differentially methylated region; early diagnosis; lung adenocarcinoma; random forest model.

MeSH terms

  • Adenocarcinoma of Lung* / diagnosis
  • Adenocarcinoma of Lung* / genetics
  • Biomarkers, Tumor / genetics
  • DNA
  • DNA Methylation
  • Early Detection of Cancer / methods
  • Humans
  • Lung Neoplasms* / diagnosis
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / pathology

Substances

  • Biomarkers, Tumor
  • DNA